文献速递心脑血管急症消化、代谢与肾脏急症

高心血管风险患者(伴或不伴糖尿病或卒中史)收缩压降至120 mmHg以下与140 mmHg以下的比较:开放标签、盲法结局随机试验

Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
PubMed 文献 · Lancet · 2024-06-27
一句话结论高心血管风险高血压患者,以收缩压<120 mmHg为目标的强化治疗较<140 mmHg减少主要血管事件(HR 0.88),但晕厥严重不良事件增加(HR 3.00)。

该开放标签、盲法结局随机对照试验从中国116家医院或社区纳入11255例高心血管风险患者(4359例糖尿病,3022例有卒中史),随机分入强化治疗组(目标诊室收缩压<120 mmHg,n=5624)或标准治疗组(目标<140 mmHg,n=5631)。随访中位数3.4年,主要终点(心肌梗死、血运重建、心力衰竭住院、卒中或心血管死亡复合终点)在强化组发生547例(9.7%),标准组623例(11.1%),HR 0.88(95%CI 0.78-0.99),p=0.028。糖尿病状态、糖尿病病程或卒中史均未见效应异质性。强化组晕厥严重不良事件更多(24例[0.4%] vs 8例[0.1%],HR 3.00,95%CI 1.35-6.68),低血压、电解质异常、伤害性跌倒或急性肾损伤的严重不良事件两组无显著差异。

要点

  • 高心血管风险高血压患者,强化降压至收缩压<120 mmHg较<140 mmHg降低主要血管事件(9.7% vs 11.1%,HR 0.88,95%CI 0.78-0.99,p=0.028)。
  • 糖尿病状态、糖尿病病程或卒中史均未见效应异质性,提示伴糖尿病或卒中史者同样可从强化降压中获益。
  • 强化组晕厥严重不良事件发生率0.4%(24/5624)高于标准组0.1%(8/5631),HR 3.00(95%CI 1.35-6.68)。
  • 低血压、电解质异常、伤害性跌倒或急性肾损伤的严重不良事件两组无显著差异。
  • 随访期间(除外最初3个月滴定)平均收缩压强化组119.1 mmHg(SD 11.1),标准组134.8 mmHg(SD 10.5)。

适用人群与场景

  • 高心血管风险患者,来自中国116家医院或社区,包括糖尿病4359例和有卒中史3022例。
  • 随机分组:强化治疗组n=5624,标准治疗组n=5631;平均年龄64.6岁(SD 7.1)。

处置流程与药物剂量

  • 强化治疗组目标诊室收缩压<120 mmHg;标准治疗组目标诊室收缩压<140 mmHg。
  • 随访期间(除外最初3个月滴定)平均收缩压:强化组119.1 mmHg(SD 11.1) vs 标准组134.8 mmHg(SD 10.5)。

红旗征与不能漏的情况

  • 强化治疗组晕厥严重不良事件更常见(24例[0.4%] vs 8例[0.1%],HR 3.00,95%CI 1.35-6.68)。

研究设计与关键结果

  • 研究类型:开放标签、盲法结局、随机对照试验;纳入11255例高心血管风险患者,来自中国116家医院或社区;强化治疗组n=5624,标准治疗组n=5631。
  • 主要终点(心肌梗死、血运重建、心力衰竭住院、卒中或心血管死亡复合终点)随访中位数3.4年:强化组547例(9.7%) vs 标准组623例(11.1%),HR 0.88(95%CI 0.78-0.99),p=0.028。
  • 糖尿病状态、糖尿病病程或卒中史均未见效应异质性。
  • 晕厥严重不良事件:强化组24例(0.4%) vs 标准组8例(0.1%),HR 3.00(95%CI 1.35-6.68)。
  • 低血压、电解质异常、伤害性跌倒或急性肾损伤的严重不良事件两组无显著差异。

证据类型、等级与局限

  • 证据类型:开放标签、盲法结局、随机对照试验(NCT04030234)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于高心血管风险高血压患者,无论是否伴糖尿病或卒中史,以收缩压<120 mmHg为目标的治疗策略较<140 mmHg可预防主要血管事件,但晕厥风险轻度增加(作者结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Uncertainty exists about whether lowering systolic blood pressure to less than 120 mm Hg is superior to that of less than 140 mm Hg, particularly in patients with diabetes and patients with previous stroke.

METHODS: In this open-label, blinded-outcome, randomised controlled trial, participants with high cardiovascular risk were enrolled from 116 hospitals or communities in China. We used minimised randomisation to assign participants to intensive treatment targeting standard office systolic blood pressure of less than 120 mm Hg or standard treatment targeting less than 140 mm Hg. The primary outcome was a composite of myocardial infarction, revascularisation, hospitalisation for heart failure, stroke, or death from cardiovascular causes, assessed by the intention-to-treat principle. This trial was registered with ClinicalTrials.gov, NCT04030234.

FINDINGS: Between Sept 17, 2019, and July 13, 2020, 11 255 participants (4359 with diabetes and 3022 with previous stroke) were assigned to intensive treatment (n=5624) or standard treatment (n=5631). Their mean age was 64·6 years (SD 7·1). The mean systolic blood pressure throughout the follow-up (except the first 3 months of titration) was 119·1 mm Hg (SD 11·1) in the intensive treatment group and 134·8 mm Hg (10·5) in the standard treatment group. During a median of 3·4 years of follow-up, the primary outcome event occurred in 547 (9·7%) participants in the intensive treatment group and 623 (11·1%) in the standard treatment group (hazard ratio [HR] 0·88, 95% CI 0·78-0·99; p=0·028). There was no heterogeneity of effects by diabetes status, duration of diabetes, or history of stroke. Serious adverse events of syncope occurred more frequently in the intensive treatment group (24 [0·4%] of 5624) than in standard treatment group (eight [0·1%] of 5631; HR 3·00, 95% CI 1·35-6·68). There was no significant between-group difference in the serious adverse events of hypotension, electrolyte abnormality, injurious fall, or acute kidney injury.

INTERPRETATION: For hypertensive patients at high cardiovascular risk, regardless of the status of diabetes or history of stroke, the treatment strategy of targeting systolic blood pressure of less than 120 mm Hg, as compared with that of less than 140 mm Hg, prevents major vascular events, with minor excess risk.

FUNDING: The Ministry of Science and Technology of China and Fuwai Hospital.

TRANSLATION: For the Mandarin translation of the abstract see Supplementary Materials section.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024. PMID: 38945140. doi:10.1016/S0140-6736(24)01028-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。